Mississippi Oncology Society

08/07/2026

On August 6, 2026, the Food and Drug Administration granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev, Replimune, Inc.), a genetically modified oncolytic viral therapy, in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melan

08/01/2026

On July 31, 2026, the Food and Drug Administration approved lutetium Lu 177 vipivotide tetraxetan (Pluvicto, Novartis Pharmaceuticals Corporation) in combination with androgen receptor pathway inhibitor (ARPI) therapy for adults with prostate-specific membrane antigen (PSMA)-positive metastatic andr

07/24/2026

On July 22, 2026, the Food and Drug Administration approved zidesamtinib (Jideytro, Nuvalent, Inc.) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who received at least one prior ROS1 tyrosine kinase inhibitor (TKI).

07/16/2026

On July 14, 2026, the Food and Drug Administration approved gedatolisib (Revtorpyk, Celcuity Inc.) in combination with fulvestrant, with or without palbociclib, for adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic bre

07/16/2026

FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

07/14/2026

https://bluetoad.com/publication/?i=867502
This issue pays tribute to MOS immediate Past President, Caleb Dulaney. He is a thoughtful leader and left the society better for his leadership. One of the largest accomplishments under his tenure was the report to the MS Legislature as a result of the comprehensive cancer care coalition task force in Dec 2025.

July 2026 Insights newsletters are published by Bay Media, Inc. as part of Strategies Magazine . To advertise contact [email protected] | 410 -647-8402 Mississippi Oncology Society’s Mission As stated on the MOS website: The mission of the Mississippi Oncology Society is to advance ex...

07/10/2026

On July 10, 2026, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) or pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex, Merck) each in combination with enfortumab vedotin-ejfv (Padcev, Astellas Pharma) as neoadjuvant treatment (before surgery) followed by adjuvan

07/10/2026

FDA approves isatuximab-irfc for subcutaneous injection for multiple myeloma indications

07/04/2026

07/01/2026

FDA approves allogeneic regulatory T cell-based immunotherapy with HSPC and T cells-vldq for use in matched donor hematopoietic stem cell transplantation